Krystal Biotech, Inc. KRYS
298.55 USD +0.65 (+0.22%)
Regular-session close
298.55 0.00 0.00%
After hours · Nov 17, 4:02 PM ET
295.06 Day range 299.80
202.99 52-week range 382.54
- YTD
- +21.10%
- 1 year
- +43.36%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Krystal Biotech, Inc. - KRYS NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal Biotech” or the “Company”) (NASDAQ: KRYS). Such investors…
defenseworld.net Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
defenseworld.net Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports.…benzinga.com Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.
benzinga.com TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.
benzinga.com RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.
benzinga.com Krystal Biotech Analyst Says Stock Weakness 'Overblown' Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.
benzinga.com Krystal Biotech Analyst Says Stock Weakness 'Overblown' Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.
seekingalpha.com Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
zacks.com Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.
schaeffersresearch.com Nasdaq Rallies as Tech Stocks Recover From Friday's Selloff Stocks are higher midday as tech stocks bounce back as peace-talk hopes grew while fanning oil prices
marketbeat.com Krystal Biotech Q3 Earnings Call Highlights Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining…
benzinga.com Krystal Biotech Q3 2026 Earnings Call Transcript Krystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.77 by 15.82 percent. This is a 22.93 percent decrease over earnings of…
globenewswire.com Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results $127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
zacks.com Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market…
globenewswire.com Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2,…
zacks.com KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
globenewswire.com Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113,…
defenseworld.net 2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the…
seekingalpha.com Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2…
fool.com Breakfast News: Week in Review Yields hit a 24-year high as SpaceX borrows $40 billion for Nvidia chips, and more…
fool.com Breakfast News: 10 Moves to Fatten Your Nest Egg Plan your retirement in 10 steps, SpaceX wants to buy $40B of Nvidia chips, and more…
defenseworld.net Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities…
defenseworld.net Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The…
zacks.com Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
